Home Page > About Clinical Trials

About Clinical Trials

Clinical trials are research studies involving people. They compare a new or different type of treatment or prevention – the ‘intervention’ - with the best treatment or prevention currently available – the ‘control’. Clinical trials may use a ‘placebo’ when no standard treatment or prevention is available.

No matter how promising a new drug, treatment or prevention may appear during tests in a laboratory, it must go through clinical trials before its benefits and risks can really be known.

Trials aim to find out if the interventions:

  • Are safe
  • Have side effects
  • Work better than the treatment or prevention used currently
  • Help people feel better

It is now widely agreed that a properly run clinical trial is the best way to assess whether a treatment or prevention is, or is not, safe and effective. Evidence from clinical trials is essential to support an authorisation to market a treatment or prevention. In the UK authorisation is controlled by a government authority known as the Medicines and Healthcare products Regulatory Agency (MHRA).

Different phases of trials

New drugs go through a number of different phases of trials, and the same principles apply to prevention interventions:

  • Phase I trials aim to test the safety of a new treatment. They look at side effects of a treatment, measuring the amount of drug absorbed (if possible) to work out the ‘tolerated dose’. Phase I trials involve only a small number of people, who are often healthy volunteers and are usually quite intensive in terms of frequent visits.
  • Phase II trials test the new treatment in increasingly larger groups of people who usually have the disease for which the treatment is to be used, or are at risk of acquiring it. In this phase, researchers are hoping to get a sense of how well the treatment or prevention might work. The size varies considerably from less than one hundred people to a thousand or more.

Treatments only move into a phase III clinical trial if the intervention is safe in phases I and II and there is a reasonable chance of effectiveness.